ALK and anaplastic large cell lymphoma: Although the CR rate reached 83 percent, patients with ALK ALCL had a median progression-free survival of just 7.5 months and a 3-year PFS of 43 percent, which was not significantly different from previous results with CHOP(-like) regimens.